Chronic Venous Occlusions Treatment Market Size by Product (Devices {Compression Devices, Endogenous Ablation [Laser Ablation, Radiofrequency Ablation], Sclerotherapy, Vein-stripping}, Drugs {Analgesics, Antibiotics, Anticoagulants}), By Application (Vari

Chronic Venous Occlusions Treatment Market Size by Product (Devices {Compression Devices, Endogenous Ablation [Laser Ablation, Radiofrequency Ablation], Sclerotherapy, Vein-stripping}, Drugs {Analgesics, Antibiotics, Anticoagulants}), By Application (Varicose Veins, Venous Stasis Ulcers, Edema, Deep Vein Thrombosis), By End-Use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2030

Global Chronic Venous Occlusions Treatment Market share is foreseen to record significant proceeds through 2030 owing to the growing prevalence of chronic venous occlusion ailments that require surgical attention. As per orpha.net statistics, hepatic veno-occlusive disease develops in 0.3 per cent to 2.3 per cent of patients who receive liver transplant, in 15% of patients treated with gemtuzumab ozogamicin, with statistics projected to rise to 40% in those with a history of GO treatment.

Factors like ongoing research studies and technological developments in deep vein thrombosis treatment would contribute to the growing market landscape between 2022-2030. In 2021, Penn State College of Engineering researchers developed an imaging technique that could become the treatment for deep vein thrombosis.

The overall market is segmented into products, applications, end-use, and regions.

Based on the product bifurcation, the devices segment is likely to amass substantial gains over 2022-2030. Mounting demand for advanced therapeutic and medical devices on grounds of their multiple advantages would contribute to the segmental expansion. Besides, the use of chronic venous occlusions treatment devices aids in controlling and preventing blood clots while increasing blood flow in legs.

In terms of application, chronic venous occlusions treatment market share from varicose veins segment is slated to surge considerably by 2030 end. Rising prevalence of varicose veins worldwide would prompt the product demand. Globally, the frequency varies between 10% to 30% of the population. Meanwhile, in the US, the prevalence is around 4,500 in 100,000 people. Numerous merits offered by the available treatment alternatives for chronic venous occlusion in treatment of varicose veins would stimulate the market prospects.

On basis of end-use, the hospitals segment is observing positive growth in the global market due to the rising adoption of technologically advanced venous devices and the availability of minimally invasive treatment options. Furthermore, the presence of medical professionals with high expertise and skills in target disorder treatment would complement the chronic venous occlusions treatment market growth trajectory between 2022-2030.

Geographically, North America chronic venous occlusions treatment market size is predicted to rise meteorically. In 2021, the regional market captured a more than 40% business share and would expand further at a notable rate through 2030. The growth would come from the elevating prevalence of chronic venous diseases, presence of major players in the continent, and reimbursement medical policies across North America.

The chronic venous occlusions treatment industry is highly consolidated and boasts presence of leading companies such as Sanofi, Boston Scientific Corporation, Bayer AG, Stryker Corporation, Bristol Myers Squibb, Cardinal Health, Tactile Medical, Pfizer Inc., and Medtronic plc, amongst others. These conglomerates are engaged in business tactics including acquisitions, mergers, partnerships, and product launches to gain a competitive advantage over others.